

## REVISITING A COMPARATIVE STUDY OF MELATONIN WITH PLACEBO IN ATTENUATION OF HEMODYNAMIC RESPONSES TO LARYNGOSCOPY AND INTUBATION

Sengul Ilker,<sup>1,2</sup> Sengul Demet<sup>3</sup>

<sup>1</sup> Giresun University Faculty of Medicine, Division of Endocrine Surgery, TR28100 Giresun, Turkey

<sup>2</sup> Giresun University Faculty of Medicine, Department of General Surgery, TR28100 Giresun, Turkey

<sup>3</sup> Giresun University Faculty of Medicine, Department of Pathology, TR28100 Giresun, Turkey

Primljen/Received: 25. 05. 2025.

Prihvaćen/Accepted: 12. 07. 2025.

Online First: July 2025.

Dear Editor,

An indolamine called melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone primarily synthesized and secreted by the pinecone-shaped gland of the cerebrum, named the conarium or epiphysis cerebri, from the amino acid tryptophan. Melatonin itself was first isolated in 1958 from the bovine pineal gland by Lerner et al., while the 17th-century philosopher René Descartes hypothesized the pineal gland of the brain (epiphysis cerebri) as the seat of the human soul—a structure paleontologists have described as an ancestral “third eye” (1–5). We do pen these lines concerning the article entitled “*A comparative study of melatonin with placebo in attenuation of hemodynamic responses to laryngoscopy and intubation*,” published in *Sanamed*, volume 19 (6). Jamwal et al. (6) reveal and address an important clinical issue—the attenuation of hemodynamic responses during laryngoscopy and endotracheal intubation—and explore the potential role of oral melatonin as premedication. The findings suggest that oral melatonin at doses of 3 mg and 6 mg effectively attenuate these pressor changes and also provides analgesic and anxiolytic effects, with the 6 mg dose showing greater effectiveness. These outcomes are valuable and align with other research indicating melatonin’s potential benefits in the perioperative period. However, while the results are promising, we wish to highlight a significant methodological aspect mentioned by the authors themselves, which warrants careful consideration when interpreting the findings. The study design allocated patients to Melatonin 3 mg, Melatonin 6 mg, and Placebo groups at the discretion of the attending anesthesiologist, rather than through a

formal randomization process. As the authors correctly point out, this lack of randomization might introduce selection bias due to subjective considerations during allocation. Although the demographic characteristics, ASA grade, and Mallampati grading were reported as comparable across the groups at baseline, the non-random allocation method means that other potentially confounding factors, not explicitly measured or reported, could have differed systematically between the groups, influencing the outcomes observed. Furthermore, the study population was limited to patients undergoing elective surgery for supratentorial tumors. While this provides a focused cohort, it also limits the generalizability of these findings to patients undergoing other types of surgery or those with different underlying pathological conditions or comorbidities beyond those listed as exclusion criteria. In addition, the authors acknowledge that the size and location of these specific tumors could potentially influence postoperative recovery characteristics. Moreover, they appropriately suggest that future studies should be conducted using randomized controlled trials with larger sample sizes and standardized methodologies to further assess melatonin’s efficacy and establish dose-response relationships. We support this recommendation. As such, a robust randomized design is crucial to minimize bias and provide more definitive evidence regarding melatonin’s role in attenuating hemodynamic responses and providing anxiolysis and analgesia in a broader surgical population. In essence, the study provides interesting preliminary evidence supporting the use of oral melatonin premedication. Nevertheless, the methodological limitation regarding the lack of randomization may be a critical factor when interpreting

these findings. To this end, we look forward to future research, ideally using randomized controlled trial designs, that will build upon these findings and provide more explicit guidance on the clinical application of melatonin in perioperative care. This issue merits further investigation. We thank Jamwal et al. (6) for their valuable study on melatonin.

**Acknowledgments:** We thank all participants in the study.

**Authors' contribution: IS:** Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Validation, Visualization, Writing-original draft, Writing-review&editing. **DS:** Conceptualization, Formal analysis, Investi-

gation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing-original draft, Writing-review&editing. All authors have read and approved the final and published version of the manuscript.

**Conflict of Interests:** The authors declare no conflicts of interest related to this article.

**Funding:** This research received no external funding.

**Note:** Artificial intelligence was not utilized as a tool in this study.

**Licensing:** This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.

## REFERENCES

1. Maliki OF, Alagbon AI, Ibitoye CM, Olayaki LA. Melatonin and Vitamin C modulate cassava diet-induced alteration in reproductive and thyroid functions. *Niger J Exp Clin Biosci.* 2021; 9(3): 133-43. doi: 10.4103/njexp.njexp\_9\_21.
2. Lane R. Of sight, and insight. *The Lancet.* 2023; 401(10371): 97. doi: 10.1016/S0140-6736(22)02589-2.
3. Soares Junior JM, Kesicioglu T, Sengul D, Sengul I. Of sight, and insight into melatonin's role in breast cancer? *Rev Assoc Med Bras.* 2023; 69(7): e697EDIT. doi: 10.1590/1806-9282.697EDIT.
4. Soares Junior JM, Detanac D, Sengul I, Dugalic S, Sengul D, Detanac D. Melatonin, menopause, and thyroid function in gynecologic endocrinology: what is the role? *Rev Assoc Med Bras.* 2024; 70(1): e701EDIT. doi: 10.1590/1806-9282.701EDIT.
5. Soares Junior JM, Sengul I, Sengul D. Melatonin, programmed death ligand-1, programmed death ligand-1, and cancer: imagine beyond the future? *Rev Assoc Med Bras.* 2025; 71(3): e0713EDIT. doi: 10.1590/1806-9282.0713EDIT.
6. Jamwal P, Zulfiqar A, Mohinder C, Singh CM, Deepika J, Iqra N, et al. A comparative study of melatonin with placebo in attenuation of hemodynamic responses to laryngoscopy and intubation. *Sanamed.* 2024; 19(1): 25-32. doi: 10.59437/sanamed19-49613.

\*Accepted papers are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of Sanamed. The final text of the article may be changed before the final publication. Accepted papers can already be cited using the year of online publication and the DOI, as follows: the author's last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI. When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

**How to cite this article:** Sengul I, Sengul D. Revisiting a comparative study of melatonin with placebo in attenuation of hemodynamic responses to laryngoscopy and intubation. *Sanamed.* Online First, July 2025. doi: 10.5937/sanamed0-59086.

## Correspondence to/Autor za korespondenciju

Prof. Demet Sengul, M.D.  
 Founder& Chair, Department of Pathology,  
 Founder, Scientific and Research Laboratories,  
 Giresun University Faculty of Medicine,  
 TR28100, Giresun, Turkey  
 email: demet.sengul.52@gmail.com  
 WoS, A-3035-2019; Scopus, 22938589200

## ORCID numbers

Demet Sengul 0000-0002-0416-0621  
 Ilker Sengul 0000-0001-5217-0755